miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting

Thursday, April 20, 2017

BOULDER, CO –April 20, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that interim results from its ongoing Phase 1 clinical study of MRG-201 will be presented at the Society for Investigative Dermatology (SID) 76th Annual Meeting being held April 26-29, 2017 in Portland, Oregon. 

Innosphere Launches Investor Network

Wednesday, April 19, 2017

Colorado - Innosphere, Colorado's leading incubator for science and technology startups, has formally launched an investor network to support investment into Innosphere client companies. The Innosphere Investor Network is a group of active, accredited investors seeking highly-vetted, investment-ready opportunities. 

Cerapedics receives $20 million loan from Oxford Finance

Wednesday, April 19, 2017

Cerapedics, Inc., a Westminster, CO-based orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries, received a $20m senior secured term loan. 

PharmaJet wins 2017 Colorado Manufacturing Awards for innovation in its category

Tuesday, April 18, 2017


Cliexa's rheumatoid arthritis app scores as the 2nd best RA app out of more than 900 tested

Tuesday, April 18, 2017

Cliexa-RA, Cliexa's rheumatoid arthritis app, has been scored as the 2nd best RA app among 19 best apps selected from 900+ apps to NIH research. 

Nivalis Therapeutics acquired by Seattle-based Alpine Immune Systems

Tuesday, April 18, 2017

A Seattle biotech company is acquiring Boulder’s Nivalis Therapeutics, merging with it to become publicly traded and use Nivalis’ $44 million in cash to fund new immunotherapy cancer and inflammatory disease treatments. 

CereScan's Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

Tuesday, April 11, 2017

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders. Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity. The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide. 

Biodesix Presents Data From Three Studies at AACR Annual Meeting

Wednesday, April 05, 2017

New data on liquid biopsy genomic tests, including multiplexed genomic assays; evaluation of biological processes underlying mass spectrometry proteomic assays of human serum. 

SomaLogic announces the appointment of long-time Board member Alister W. Reynolds as Chief Executive Officer

Wednesday, April 05, 2017

Former CEO Byron Hewett steps down after successfully building the foundation for SomaLogic’s future growth. 

ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

Tuesday, April 04, 2017

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration (CFDA).